



CLINICAL GUIDELINE

Herpes zoster ophthalmicus assessment - casualty

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Version Number:	5
Does this version include changes to clinical advice:	Yes
Date Approved:	1 st May 2024
Date of Next Review:	1 st November 2027
Lead Author:	Caoimhe Henry
Approval Group:	Medicines Utilisation Subcommittee of ADTC

Important Note:

The Intranet version of this document is the only version that is maintained. Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.

Herpes Zoster Ophthalmicus Casualty Protocol

History

Blurred vision	Headache, fever, lethargy
Eye pain or photophobia	Previous episodes
Redness, discharge from eye	Past ophthalmic history
Rash – duration, distribution	History of immunosuppression

Examination

VA/ IOP/ Pupil assessment	Motility assessment
Dermatological exam/ adnexa	Slit lamp anterior segment assessment

Corneal Sensation

Swab for Viral PCR if any doubt

Dilated Fundoscopy

Examination features						
Dermatological	Lids	Conjunctiva	Cornea	Uveitis/ Scleritis/ Episcleritis	Optic neuropathy	Motility
Unilateral vesicular rash which respects midline Typically, V1 but can have V2/V3 distribution Hutchison sign – tip of nose involved	Oedema Blepharitis, trichiasis Lagophthalmos – beware of exposure Cicatricial changes	Hyperaemia Petechial haemorrhage Papillae/ follicles Mucopurulent discharge Pseudomembrane	Exposure keratopathy Pseudodendrite Disciform keratitis Neurotrophic keratitis Peripheral corneal ulceration Secondary bacterial infection	Often delayed onset Endothelial KP's Anterior chamber activity Nodular lesion	Reduced VA Disc swelling/ hyperaemia	Nerve palsy Pupils Orbicularis function if suspect CN III palsy

HZO Category	Signs		Basic Treatment Approach		Follow-up
Cutaneous	Unilateral vesicular rash typically V1 distribution (can have V2 or V3)		Warm bathing crusting lesions/ lid hygiene advice	PO Aciclovir 800mg x5 per day 1/52	GP if no ocular involvement
Conjunctivitis	Conjunctival hyperaemia without corneal involvement		Lid hygiene advice Consider topical Ganciclovir 0.15% x5 per day	PO Aciclovir 800mg x5 per day 1/52	1/52 corneal PCC
Keratitis	Epithelial	Infiltrate	Refer to Bacterial Keratitis Protocol	PO Aciclovir 800mg x5 per day 1/52	1/52 corneal PCC
		No infiltrate	Lubricants Consider topical Ganciclovir 0.15% x5 per day		
	Stromal	Epithelial defect	Withhold topical steroids		
		Epithelium intact	Topical Steroid QID e.g. Predforte		
	Neurotrophic		As epithelial + intense lubrication e.g. Evolve HA hourly		
Anterior uveitis	AC activity	Epithelial defect	Withhold topical steroids until epithelium healed Topical cyclopentolate 1% TDS	PO Aciclovir 800mg x5 per day 1/52	1/52 corneal PCC
		Epithelium intact	Tapering course topical steroid e.g. Predforte Topical cyclopentolate 1% TDS		
Scleritis, Vitritis, Retinitis, Optic neuropathy, nerve palsy or history of immunosuppression			SENIOR REVIEW REQUIRED – may need systemic antiviral therapy +/- steroids. Consider discussion with Infectious Diseases team if immunosuppressed.		

Elevated IOP

- < 35mmHg Topical IOP lowering agents e.g. Timolol
- > 35mmHg Topical IOP lowering agents + PO Diamox

Pain

- Advise regular simple analgesia (paracetamol/ ibuprofen)
- Refer to GP for consideration of neuropathic agents as required